|
Dec 18
|
Arcutis shares jump after FDA approves drug for chronic skin condition
|
|
Nov 29
|
FDA Accepts Arcutis’ Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6
|
|
Nov 17
|
After Plunging -35.64% in 4 Weeks, Here's Why the Trend Might Reverse for Arcutis Biotherapeutics, Inc. (ARQT)
|
|
Nov 17
|
Polar Capital Holdings Plc Bolsters Portfolio with Arcutis Biotherapeutics Inc Stake
|
|
Nov 5
|
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2023 Earnings Call Transcript
|
|
Nov 3
|
Arcutis Biotherapeutics Inc (ARQT) Reports Q3 2023 Earnings: Revenue Soars to $38.1 Million
|
|
Nov 3
|
Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update
|
|
Nov 2
|
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Sep 27
|
Arcutis Appoints L. Todd Edwards as Chief Commercial Officer
|
|
Sep 27
|
Roivant Sciences Ltd. (ROIV) Moves 21.6% Higher: Will This Strength Last?
|
|
Sep 25
|
Mizuho reaffirms 'Buy' recommendation for Arcutis Biotherapeutics, amidst mixed institutional sentiment
|
|
Sep 25
|
New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic Dermatitis
|